Avalo Therapeutics financials
$15.58+3.32%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $59.0K | $0.00 | $0.00 | $0.00 | $192.0K | $249.0K | $0.00 | $0.00 | $571.0K | $236.0K |
| Gross profit | $0.00 | $0.00 | $59.0K | $0.00 | $0.00 | $0.00 | $105.0K | $963.0K | -$343.0K | $80.0K | $792.0K | -$11.0K |
| Gross margin | — | — | 100.0% | — | — | — | 54.7% | 386.7% | — | — | 138.7% | −4.7% |
| Operating income | -$31.5M | -$20.9M | -$19.7M | -$19.2M | -$19.3M | -$14.7M | -$13.3M | -$12.9M | -$9.6M | -$32.8M | -$7.7M | -$3.8M |
| Net income | -$36.4M | -$19.6M | -$13.7M | -$30.6M | -$20.8M | -$13.1M | -$35.2M | $5.5M | $4.4M | -$121.3M | -$8.2M | -$5.2M |
| Net margin | — | — | −23254.2% | — | — | — | −18313.5% | 2193.6% | — | — | −1430.5% | −2215.3% |
| Diluted EPS | $-0.83 | $-0.98 | $-0.75 | $-2.19 | $-1.92 | $-1.25 | $-3.29 | $-2.83 | $-14.07 | $-141.14 | — | $-26.83 |
| EBITDA | -$31.5M | -$20.9M | -$19.7M | -$19.1M | -$19.2M | -$14.5M | -$13.2M | -$12.8M | -$9.5M | -$32.7M | -$3.7M | -$3.7M |
| Operating cash flow | -$20.0M | -$17.7M | -$14.2M | -$16.4M | -$11.4M | -$9.5M | -$15.0M | -$11.5M | -$16.3M | -$6.2M | -$2.8M | -$6.8M |
| Free cash flow | -$20.0M | -$17.7M | -$14.2M | -$16.4M | -$11.4M | -$9.5M | -$15.0M | -$11.5M | -$16.3M | -$6.2M | -$2.8M | -$6.8M |
| Diluted shares | 43.6M | 20.1M | 18.3M | 14.0M | 10.8M | 10.5M | 10.7M | 10.8M | 7.7M | 0.9M | — | 0.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $85.4M | $25.0M | $15.9M | $27.0M | $42.3M | $125.0M |
| Short-term investments | $314.9M | $57.0M | $82.5M | $84.7M | $71.0M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $490.8M | $99.9M | $116.5M | $125.1M | $126.6M | $138.5M |
| Total liabilities | $42.1M | $31.6M | $33.4M | $33.6M | $22.0M | $15.9M |
| Shareholders' equity | $448.7M | $68.3M | $83.0M | $91.5M | $104.6M | $122.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology